Jubilant Pharmova Q1 Review – Radiopharma On A Gradual Recovery Path: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Jubilant Pharmova Ltd. delivered in line earnings, despite a better than expected revenue in Q1 FY22.

The Covid-19 related business led to a strong y-o-y revenue growth.

However, reduced number of lung procedures in the radiopharma segment, increased price erosion in the Sartans portfolio, and price erosion in the base portfolio in the generics segment led to lower-than-expected profitability, offsetting benefits of higher revenue.

We have reduced Jubilant Pharmova’s FY22E/FY23E earnings per share estimate by 14% each to factor in:

  1. delay in potential products on account of the import alert at Roorkee,

  2. higher competitive pressures in the generics portfolio,

  3. gradual recovery in radiopharma sales, and

  4. lower operating leverage.

Click on the attachment to read the full report:

Motilal Oswal Jubilant Pharmova Q1FY22 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
editorpen Governmental News Finance News

Source link

Back to top button